TOLREMO Therapeutics AG has appointed Kenneth C. Anderson to its scientific advisory board as the company expands the clinical development programme for its lead candidate TT125-802 beyond solid tumours and into haematologic malignancies. Over four decades Dr Anderson has conducted translational and clinical research in multiple myeloma and his work has directly contributed to approval by the US Food and Drug Administration of groundbreaking therapies.
He is the Kraft Family Professor of Medicine at Harvard Medical School and the director of the LeBow Institute for Myeloma Therapeutics, both US. TOLREMO is expanding its development programme into multiple myeloma as an additional indication for its CBP/p300 bromodomain inhibitor programme which has a favourable safety profile.
TOLREMO Therapeutics announced the appointment on 30 October 2025.
Copyright 2025 Evernow Publishing Ltd.